UA83915C2 - Многофазный препарат для контрацепции на основе натурального эстрогена - Google Patents

Многофазный препарат для контрацепции на основе натурального эстрогена

Info

Publication number
UA83915C2
UA83915C2 UAA200611799A UAA200611799A UA83915C2 UA 83915 C2 UA83915 C2 UA 83915C2 UA A200611799 A UAA200611799 A UA A200611799A UA A200611799 A UAA200611799 A UA A200611799A UA 83915 C2 UA83915 C2 UA 83915C2
Authority
UA
Ukraine
Prior art keywords
natural estrogen
preparation based
preparation
contraceptive preparation
phase
Prior art date
Application number
UAA200611799A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ян Эндрикат
Бернд Дюстерберг
Original Assignee
Байер Шеринг Фарма Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA83915(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Шеринг Фарма Акциенгезелльшафт filed Critical Байер Шеринг Фарма Акциенгезелльшафт
Publication of UA83915C2 publication Critical patent/UA83915C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Abstract

Изобретение касается многофазного препарата для контрацепции на основе натурального эстрогена в комбинации с синтетическим гестагеном, который по сравнению с обычными известными препаратами, угнетающими овуляцию, обеспечивает более высокую контрацептивную надежность.
UAA200611799A 2004-04-20 2005-04-15 Многофазный препарат для контрацепции на основе натурального эстрогена UA83915C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004019743A DE102004019743B4 (de) 2004-04-20 2004-04-20 Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
PCT/EP2005/004022 WO2005102247A2 (de) 2004-04-20 2005-04-15 Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens

Publications (1)

Publication Number Publication Date
UA83915C2 true UA83915C2 (ru) 2008-08-26

Family

ID=34979546

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200611799A UA83915C2 (ru) 2004-04-20 2005-04-15 Многофазный препарат для контрацепции на основе натурального эстрогена

Country Status (38)

Country Link
US (3) US8071577B2 (ru)
EP (1) EP1740163B2 (ru)
JP (1) JP4908399B2 (ru)
KR (1) KR20060134168A (ru)
CN (1) CN1946383B (ru)
AR (2) AR048830A1 (ru)
AT (1) ATE473734T1 (ru)
AU (1) AU2005235418C1 (ru)
BR (1) BRPI0510005A (ru)
CA (1) CA2561839C (ru)
CR (1) CR8695A (ru)
CY (1) CY1111292T1 (ru)
DE (2) DE102004019743B4 (ru)
DK (1) DK1740163T4 (ru)
EA (1) EA010313B1 (ru)
EC (1) ECSP067000A (ru)
ES (1) ES2348038T5 (ru)
GT (1) GT200500093A (ru)
HK (1) HK1099701A1 (ru)
HR (1) HRP20100513T4 (ru)
IL (2) IL178510A (ru)
ME (1) ME01183B (ru)
MX (1) MXPA06012213A (ru)
MY (1) MY143669A (ru)
NO (1) NO344098B1 (ru)
NZ (1) NZ550417A (ru)
PA (1) PA8630901A1 (ru)
PE (1) PE20060308A1 (ru)
PL (1) PL1740163T5 (ru)
PT (1) PT1740163E (ru)
RS (1) RS51434B2 (ru)
SI (1) SI1740163T2 (ru)
SV (1) SV2006002090A (ru)
TW (1) TWI351960B (ru)
UA (1) UA83915C2 (ru)
UY (1) UY28863A1 (ru)
WO (1) WO2005102247A2 (ru)
ZA (1) ZA200609594B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
PT1937274E (pt) * 2005-10-13 2012-05-28 Bayer Pharma AG Utilização de valerato de estradiol em combinação com dienogest para a terapia oral da hemorragia uterina disfuncional em conjunto com uma contracepção oral
ATE424828T1 (de) * 2005-10-13 2009-03-15 Bayer Schering Pharma Ag Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
ES2558030T3 (es) 2006-03-02 2016-02-01 Warner Chilcott Company, Llc Método anticonceptivo oral multifásico de ciclo prolongado
DE102006010329A1 (de) * 2006-03-06 2007-09-13 Höltge, Michael, Dipl.-Med. Hormonelles Kontrazeptivum auf der Basis eines Estrogens, eines Gestagens oder einer Kombination von Estrogenen und Gestagenen unter der Zugabe von Testosteron
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US20090117184A1 (en) * 2007-11-05 2009-05-07 Sabine Fricke Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception
TW201306825A (zh) * 2011-05-11 2013-02-16 Kirax Corp 狀況治療之改良套裝

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) * 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) * 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) * 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
DE2431704A1 (de) 1974-07-02 1976-01-22 Asche Ag Stufenkombinationspraeparate per kontrazeption
DE2645307A1 (de) 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
JPS6019734B2 (ja) 1977-05-12 1985-05-17 三共株式会社 安定なプロスタグランジンe類製剤の製法
US4272270A (en) 1979-04-04 1981-06-09 Petrochem Consultants, Inc. Cryogenic recovery of liquid hydrocarbons from hydrogen-rich
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (de) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (ru) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4313926A1 (de) * 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4339934C2 (de) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
WO1998004268A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
CN1186023C (zh) * 1996-07-26 2005-01-26 惠氏公司 双相避孕方法及包含孕激素和雌激素组合物的药剂盒
BR9710566A (pt) 1996-07-26 1999-08-17 American Home Prod M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6312772B1 (en) * 1997-10-20 2001-11-06 Hoechst Celanese Corporation Multilayer laminate formed from a substantially stretched non-molten wholly aromatic liquid crystalline polymer and non-polyester thermoplastic polymer
DE19908762A1 (de) * 1999-02-18 2000-08-31 Jenapharm Gmbh Verwendung von Dienogest in hoher Dosierung
DE10045380A1 (de) 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
US6699820B2 (en) * 2001-03-02 2004-03-02 Hartmut Ulrich Bielefeldt Method for making a superconductor with enhanced current carrying capability
KR20040037097A (ko) * 2001-09-29 2004-05-04 솔베이 파머슈티컬스 게엠베하 에스트로겐/게스타겐 조합 제제 및 그 이용
EP1462106A1 (en) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
WO2004112797A1 (en) 2003-06-25 2004-12-29 Schering Ag Hormone replacement- and depression therapy comprising dienogest
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
EP2392333A1 (en) * 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
ATE424828T1 (de) 2005-10-13 2009-03-15 Bayer Schering Pharma Ag Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Also Published As

Publication number Publication date
HRP20100513T1 (en) 2010-11-30
KR20060134168A (ko) 2006-12-27
PE20060308A1 (es) 2006-05-25
US20110124612A1 (en) 2011-05-26
ES2348038T3 (es) 2010-11-29
PL1740163T3 (pl) 2010-12-31
AU2005235418C1 (en) 2015-05-21
CN1946383B (zh) 2010-06-09
SI1740163T1 (sl) 2010-11-30
EP1740163B2 (de) 2020-01-15
JP4908399B2 (ja) 2012-04-04
NO20065292L (no) 2007-01-17
DE102004019743B4 (de) 2008-11-27
RS51434B (en) 2011-04-30
NZ550417A (en) 2010-01-29
CN1946383A (zh) 2007-04-11
EP1740163B1 (de) 2010-07-14
PT1740163E (pt) 2010-09-28
AR048830A1 (es) 2006-05-31
NO344098B1 (no) 2019-09-02
IL178510A0 (en) 2007-02-11
UY28863A1 (es) 2005-11-30
GT200500093A (es) 2006-04-17
CY1111292T1 (el) 2015-08-05
MXPA06012213A (es) 2007-01-17
ATE473734T1 (de) 2010-07-15
HK1099701A1 (en) 2007-08-24
TWI351960B (en) 2011-11-11
WO2005102247A2 (de) 2005-11-03
ECSP067000A (es) 2006-12-29
DE102004019743A1 (de) 2005-11-24
AU2005235418B2 (en) 2009-08-06
MY143669A (en) 2011-06-30
IL239861A0 (en) 2015-08-31
RS51434B2 (sr) 2020-11-30
PL1740163T5 (pl) 2020-10-05
CR8695A (es) 2008-07-29
CA2561839C (en) 2009-09-29
ES2348038T5 (es) 2020-09-14
WO2005102247A3 (de) 2006-01-12
ME01183B (me) 2013-03-20
EA200601844A1 (ru) 2007-04-27
IL178510A (en) 2015-08-31
TW200534860A (en) 2005-11-01
PA8630901A1 (es) 2006-05-16
BRPI0510005A (pt) 2007-09-18
CA2561839A1 (en) 2005-11-03
HRP20100513T4 (hr) 2020-10-02
SI1740163T2 (sl) 2020-04-30
EP1740163A2 (de) 2007-01-10
ZA200609594B (en) 2008-04-30
JP2007533681A (ja) 2007-11-22
US8071577B2 (en) 2011-12-06
SV2006002090A (es) 2006-02-15
DK1740163T3 (da) 2010-10-18
AR084229A2 (es) 2013-05-02
DK1740163T4 (da) 2020-04-06
US20070259840A1 (en) 2007-11-08
DE502005009904D1 (de) 2010-08-26
US20100173877A1 (en) 2010-07-08
EA010313B1 (ru) 2008-08-29
AU2005235418A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
UA83915C2 (ru) Многофазный препарат для контрацепции на основе натурального эстрогена
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
MX2012013787A (es) Composiciones y metodos para estimular magp-1 y mejorar la apariencia de la piel.
WO2009088401A3 (en) Immunostimulatory combinations of tlr3 ligands with tlr2 and/or tlr9 agonists and methods of use
MX2012004339A (es) Control de perfil de pitadas.
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
IN2012DN01898A (ru)
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
MX2007000979A (es) Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada.
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
WO2009148620A3 (en) Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
TW200602063A (en) Compositions and methods for treatment of premenstrual dysphoric disorder
CA134604S (en) Electrical contactors
CN204050723U (zh) 安全带
UA98638C2 (ru) Композиция для регулирования трофизма волосяных фолликулов и/или продуцирования кожного сала на коже
PH12017501257A1 (en) Foot-and-mouth disease vaccine
WO2006069048A3 (en) Reduction of hair growth
MX360325B (es) Composicion de tratamiento para el cabello.
MX344189B (es) Formulaciones de mazindol.
MY190399A (en) A composition comprising cistanche and ginkgo extracts, the composition useful for improving memory of a subject
WO2006029300A8 (en) Flavivirus variants having phenotypic variation and immunogenic compositions thereof
CA98132S (en) Tabletop folder/inserter
CN105250304A (zh) 防秃发生发剂
CN202706448U (zh) 新型地板连接件
CN104434923A (zh) 防秃发生发剂